$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Contrast-enhanced ultrasound imaging makes use of microbubble contrast agents to visualize and characterize the vascular environment. These agents enable noninvasive assessment of the microcirculation, vascularity and cardiovascular function. In addition, modification of the bubble surface can result in targeted microbubble binding to endothelial biomarkers, as demonstrated in preclinical applications of angiogenesis, atherosclerosis and inflammation 1,2 making molecular ultrasound imaging of vascular events possible. Contrast enhanced ultrasound can therefore be used to identify the complex and diverse environments that influence healthy and diseased vascular states3-5.
In the past number of years, interest in the utility of microbubble imaging has extended to the versatile mouse embryo model. As a model of mammalian development, introduction of microbubbles into the embryonic vasculature enhances physiological study of the developing circulatory system (e.g., blood flow, cardiac output) and in cases of transgenic and targeted mutant mouse models of cardiac disease 6,7, may yield insights into how genetic factors alter cardiovascular function. In fact, quantitative and qualitative 2D analyses of embryonic brain vasculature have already been achieved8. Furthermore, the mouse embryo presents as an excellent model for examining the binding of targeted microbubbles to vascular markers in vivo. Bartelle et al.9, for instance, have introduced avidin microbubbles into embryo cardiac ventricles to assess targeted binding in Biotag-BirA transgenic embryos and examine vascular anatomy. The generation of heterozygous and homozygous mouse models can be also be used as a surrogate for tumor model studies aiming to define the quantitative nature of molecular ultrasound - an important benchmark in translating this technique to the clinic.
Microbubbles are most frequently introduced to the embryonic circulation via intra-cardiac injections into single embryos exposed through a laparotomy8-10. In utero injections, however, face a number of challenges. These include injection guidance, the need to counter motion in the mother and exteriorized embryo, maintenance of hemodynamic viability in the mother and exteriorized embryos, addressing long-term effects of anesthesia and complications due to bleeding11. Therefore, the goal of the investigation was to develop a technique for injecting microbubbles into isolated living late-stage embryos12. This option offers more freedom in terms of injection control and positioning, reproducibility of the imaging plane without obstruction, and simplified image analysis and quantification.
In the present study, we outline a novel procedure for the injection of microbubbles into living murine embryos for the purposes of studying microbubble kinetic behavior and of studying targeted microbubble binding to endogenous endothelial surface markers. Non-linear contrast specific ultrasound imaging is used to measure of a number of basic perfusion parameters including peak enhancement (PE), wash-in rate and time to peak (TTP) in isolated E17.5 embryos. We also demonstrate the validity of the embryo model for assessing the quantitative nature of molecular ultrasound in an embryonic endoglin loss of function transgenic mouse model, where endoglin is a clinically relevant target due to its high expression in vascular endothelial cells at sites of active angiogenesis13. The adhesion of endoglin-targeted (MBE), rat isotype IgG2 control (MBC) and untargeted (MBU) microbubbles is evaluated in heterozygous endoglin (Eng+/-) and homozygous endoglin (Eng+/+) expressing embryos. Analysis of the targeted binding reveals that molecular ultrasound is capable of differentiating between endoglin genotypes and relating receptor densities to quantifiable molecular ultrasound levels.